Niemann-Pick Disease Type C
New Niemann-Pick disease type C research, summarized each month in plain language.
2026 so far: So far in 2026 (January to September), evidence on arimoclomol expanded from trial summaries to real-world early access follow-up suggesting broadly stable severity scores, while several reports clarified concrete ways NPC diagnosis can be missed or mimicked. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Arimoclomol follow-up. Shifted from trial summaries to longer real-world follow-up.
- Leucine-based therapies. Evidence remained mixed: short-term signals, limited durability data.
- Care pathways. More detailed consensus roadmaps for diagnosis and follow-up appeared.
- Avoiding missed diagnosis. More concrete reasons for false positives and missed variants emerged.
- Monitoring signals. New candidate markers were reported without validation to outcomes.
New
September 2026
- Gene change range. Reports from India showed many different NPC1 and NPC2 changes.
- Missing DNA segments. Testing detected exon deletions that some gene tests may miss.
- Liver and spleen signs. Some people had mainly liver and spleen findings at diagnosis.
August 2026
- Arimoclomol outcomes. Average disease severity scores were described as broadly stable.
- Side effect reports. Many side effects were noted, but few were linked to arimoclomol.
- Early puberty report. One child had early puberty monitored during hormone-blocking treatment.
July 2026
- RNA test clues. RNA testing found NPC1 changes missed by standard DNA tests.
- Wilson-like lab results. NPC can resemble Wilson disease on some copper-related tests.
- Miglustat case reports. Reports showed mixed symptom changes after starting miglustat.
- Early lab signals. Lab studies suggested pathway changes, not yet shown in people.
June 2026
- Infant add-on trial. Arimoclomol plus miglustat was doable, but benefit was unclear.
- Side effect findings. Most side effects were mild, but one infant had higher liver enzymes.
- Blood marker patterns. LysoSM-509 was high in all patients, and HDL was often low.
May 2026
- Genetic testing to identify NPC. Experts reached full agreement that Niemann-Pick disease type C (NPC) should be identified using genetic testing.
- NPC in adult movement symptoms. NPC was noted as a genetic cause to consider when adults present with movement-related symptoms.
April 2026
- Medication-related test confusion. Sertraline use was linked to NPC-like biomarker patterns in some people, which could complicate interpretation of screening results.
- Updated NPC care guidance. An international consensus document was updated to help standardize how NPC is diagnosed, treated, and followed.
- Possible CSF monitoring marker. Small studies reported higher extracellular vesicle levels in cerebrospinal fluid in NPC, but this is not yet validated for routine use.
- Microglia stress patterns. Laboratory and animal studies described specific microglia stress states and cholesterol-handling changes linked to NPC1 disruption.
March 2026
- Care pathway. An Australian consensus document described a shared step-by-step plan for diagnosing NP-C and organizing follow-up care.
- Hearing loss mechanism (mouse). In an NP-C mouse model, hearing loss was linked to changes in inner-ear support cells and reduced inner-ear electrical potential.
- Which NPC1 variants are harmful. A laboratory model was used to help classify which NPC1 gene changes are likely to disrupt protein function.
- Gene therapy timing (mouse). In NP-C mice, gene therapy results differed by timing and by how much treatment reached the brain.
February 2026
- Neuron-like NPC cell model. Human neuron-like cells with the NPC1 I1061T change showed cholesterol buildup and lysosome dysfunction, creating a lab model for testing research interventions.
- Two intervention effects. In this model, one lab intervention lowered stored cholesterol and another increased NPC1 protein levels, and both produced only partial improvement in disease-like cell features.
- NPC1 misfolding signal. The altered NPC1 protein behaved like a misfolded protein that is retained inside cells, which is consistent with protein-stabilizing approaches as a research direction.
January 2026
- Arimoclomol progression. Linked to slower score worsening over about 12 months.
- Levacetylleucine symptoms. Linked to short-term coordination gains; long-term effects stayed unclear.
- Side effects and warnings. Side effects were common, and boxed warnings were noted.
- Marker test limits. Blood and urine markers did not confirm NPC in screening.
Get the monthly update by email
Subscribe here to receive an email when a new monthly Niemann-Pick disease type C update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).